195 related articles for article (PubMed ID: 36216349)
1. Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of
Lowe MA; Cardenas A; Valentin JP; Zhu Z; Abendroth J; Castro JL; Class R; Delaunois A; Fleurance R; Gerets H; Gryshkova V; King L; Lorimer DD; MacCoss M; Rowley JH; Rosseels ML; Royer L; Taylor RD; Wong M; Zaccheo O; Chavan VP; Ghule GA; Tapkir BK; Burrows JN; Duffey M; Rottmann M; Wittlin S; Angulo-Barturen I; Jiménez-Díaz MB; Striepen J; Fairhurst KJ; Yeo T; Fidock DA; Cowman AF; Favuzza P; Crespo-Fernandez B; Gamo FJ; Goldberg DE; Soldati-Favre D; Laleu B; de Haro T
J Med Chem; 2022 Oct; 65(20):14121-14143. PubMed ID: 36216349
[TBL] [Abstract][Full Text] [Related]
2. Substrate Peptidomimetic Inhibitors of P. falciparum Plasmepsin X with Potent Antimalarial Activity.
Richardson LW; Ashton TD; Dans MG; Nguyen N; Favuzza P; Triglia T; Hodder AN; Ngo A; Jarman KE; Cowman AF; Sleebs BE
ChemMedChem; 2022 Sep; 17(18):e202200306. PubMed ID: 35906744
[TBL] [Abstract][Full Text] [Related]
3. Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life Cycle.
Favuzza P; de Lera Ruiz M; Thompson JK; Triglia T; Ngo A; Steel RWJ; Vavrek M; Christensen J; Healer J; Boyce C; Guo Z; Hu M; Khan T; Murgolo N; Zhao L; Penington JS; Reaksudsan K; Jarman K; Dietrich MH; Richardson L; Guo KY; Lopaticki S; Tham WH; Rottmann M; Papenfuss T; Robbins JA; Boddey JA; Sleebs BE; Sabroux HJ; McCauley JA; Olsen DB; Cowman AF
Cell Host Microbe; 2020 Apr; 27(4):642-658.e12. PubMed ID: 32109369
[TBL] [Abstract][Full Text] [Related]
4. Design of Novel Series of Antimalarial PMX Inhibitors with Increased Half-Life via Molecular Property Optimization.
Sakata K; Lowe MA; Xuan M; Bruffaerts J; Stasi LP; Lallemand B; Cardenas A; Taylor RD; Vidler LR; King L; Valentin JP; Laleu B; de Haro T
ACS Med Chem Lett; 2023 Nov; 14(11):1582-1588. PubMed ID: 37974949
[TBL] [Abstract][Full Text] [Related]
5. Macrocyclic Peptidomimetic Plasmepsin X Inhibitors with Potent
Kovada V; Withers-Martinez C; Bobrovs R; Ce Rule HN; Liepins E; Grinberga S; Hackett F; Collins CR; Kreicberga A; Jiménez-Díaz MB; Angulo-Barturen I; Rasina D; Suna E; Jaudzems K; Blackman MJ; Jirgensons A
J Med Chem; 2023 Aug; 66(15):10658-10680. PubMed ID: 37505188
[TBL] [Abstract][Full Text] [Related]
6. Bridging the Gap in Malaria Parasite Resistance, Current Interventions, and the Way Forward from in Silico Perspective: A Review.
Kumi RO; Oti B; Abo-Dya NE; Alahmdi MI; Soliman MES
Molecules; 2022 Nov; 27(22):. PubMed ID: 36432016
[TBL] [Abstract][Full Text] [Related]
7. Plasmepsins IX and X are essential and druggable mediators of malaria parasite egress and invasion.
Nasamu AS; Glushakova S; Russo I; Vaupel B; Oksman A; Kim AS; Fremont DH; Tolia N; Beck JR; Meyers MJ; Niles JC; Zimmerberg J; Goldberg DE
Science; 2017 Oct; 358(6362):518-522. PubMed ID: 29074774
[TBL] [Abstract][Full Text] [Related]
8. A multistage antimalarial targets the plasmepsins IX and X essential for invasion and egress.
Pino P; Caldelari R; Mukherjee B; Vahokoski J; Klages N; Maco B; Collins CR; Blackman MJ; Kursula I; Heussler V; Brochet M; Soldati-Favre D
Science; 2017 Oct; 358(6362):522-528. PubMed ID: 29074775
[TBL] [Abstract][Full Text] [Related]
9. Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivax.
Hodder AN; Christensen J; Scally S; Triglia T; Ngo A; Birkinshaw RW; Bailey B; Favuzza P; Dietrich MH; Tham WH; Czabotar PE; Lowes K; Guo Z; Murgolo N; Lera Ruiz M; McCauley JA; Sleebs BE; Olsen D; Cowman AF
Structure; 2022 Jul; 30(7):947-961.e6. PubMed ID: 35460613
[TBL] [Abstract][Full Text] [Related]
10.
Sharma PP; Kumar S; Kaushik K; Singh A; Singh IK; Grishina M; Pandey KC; Singh P; Potemkin V; Poonam ; Singh G; Rathi B
J Biomol Struct Dyn; 2022 Nov; 40(18):8352-8364. PubMed ID: 33870856
[TBL] [Abstract][Full Text] [Related]
11. Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors.
Moura PA; Dame JB; Fidock DA
Antimicrob Agents Chemother; 2009 Dec; 53(12):4968-78. PubMed ID: 19752273
[TBL] [Abstract][Full Text] [Related]
12. Screening the Medicines for Malaria Venture Pathogen Box for invasion and egress inhibitors of the blood stage of Plasmodium falciparum reveals several inhibitory compounds.
Dans MG; Weiss GE; Wilson DW; Sleebs BE; Crabb BS; de Koning-Ward TF; Gilson PR
Int J Parasitol; 2020 Mar; 50(3):235-252. PubMed ID: 32135179
[TBL] [Abstract][Full Text] [Related]
13. Subtilisin-like Serine Protease 1 (SUB1) as an Emerging Antimalarial Drug Target: Current Achievements in Inhibitor Discovery.
Lidumniece E; Withers-Martinez C; Hackett F; Blackman MJ; Jirgensons A
J Med Chem; 2022 Oct; 65(19):12535-12545. PubMed ID: 36137276
[TBL] [Abstract][Full Text] [Related]
14. Plasmodium falciparum ookinete expression of plasmepsin VII and plasmepsin X.
Li F; Bounkeua V; Pettersen K; Vinetz JM
Malar J; 2016 Feb; 15():111. PubMed ID: 26911483
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.
Gaur AH; McCarthy JS; Panetta JC; Dallas RH; Woodford J; Tang L; Smith AM; Stewart TB; Branum KC; Freeman BB; Patel ND; John E; Chalon S; Ost S; Heine RN; Richardson JL; Christensen R; Flynn PM; Van Gessel Y; Mitasev B; Möhrle JJ; Gusovsky F; Bebrevska L; Guy RK
Lancet Infect Dis; 2020 Aug; 20(8):964-975. PubMed ID: 32275867
[TBL] [Abstract][Full Text] [Related]
16. Antimalarial evaluation of copper(II) nanohybrid solids: inhibition of plasmepsin II, a hemoglobin-degrading malarial aspartic protease from Plasmodium falciparum.
Mohapatra SC; Tiwari HK; Singla M; Rathi B; Sharma A; Mahiya K; Kumar M; Sinha S; Chauhan SS
J Biol Inorg Chem; 2010 Mar; 15(3):373-85. PubMed ID: 19946719
[TBL] [Abstract][Full Text] [Related]
17. Antimalarial synergy of cysteine and aspartic protease inhibitors.
Semenov A; Olson JE; Rosenthal PJ
Antimicrob Agents Chemother; 1998 Sep; 42(9):2254-8. PubMed ID: 9736544
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antimalarial activity of plasmepsin V inhibitors by modification of the P
Nguyen W; Hodder AN; de Lezongard RB; Czabotar PE; Jarman KE; O'Neill MT; Thompson JK; Jousset Sabroux H; Cowman AF; Boddey JA; Sleebs BE
Eur J Med Chem; 2018 Jun; 154():182-198. PubMed ID: 29800827
[TBL] [Abstract][Full Text] [Related]
19. Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183.
de Vries LE; Jansen PAM; Barcelo C; Munro J; Verhoef JMJ; Pasaje CFA; Rubiano K; Striepen J; Abla N; Berning L; Bolscher JM; Demarta-Gatsi C; Henderson RWM; Huijs T; Koolen KMJ; Tumwebaze PK; Yeo T; Aguiar ACC; Angulo-Barturen I; Churchyard A; Baum J; Fernández BC; Fuchs A; Gamo FJ; Guido RVC; Jiménez-Diaz MB; Pereira DB; Rochford R; Roesch C; Sanz LM; Trevitt G; Witkowski B; Wittlin S; Cooper RA; Rosenthal PJ; Sauerwein RW; Schalkwijk J; Hermkens PHH; Bonnert RV; Campo B; Fidock DA; Llinás M; Niles JC; Kooij TWA; Dechering KJ
Nat Commun; 2022 Apr; 13(1):2158. PubMed ID: 35444200
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of Plasmepsin II-potential antimalarial agents.
Corminboeuf O; Dunet G; Hafsi M; Grimont J; Grisostomi C; Meyer S; Binkert C; Bur D; Jones A; Prade L; Brun R; Boss C
Bioorg Med Chem Lett; 2006 Dec; 16(24):6194-9. PubMed ID: 17000102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
